Regional hyperthermia in high-risk soft tissue sarcomas.
1University Hospital Medical Center Grosshadern, Medical Clinic III and Helmholtz Zentrum münchen - German Research Center for Environmetal Health, Munich, Germany. rolf.issels@med.uni-muenchen.de
Current Opinion in Oncology
|June 6, 2008
Summary
Regional hyperthermia combined with chemotherapy is a promising preoperative treatment for high-risk soft tissue sarcomas. This approach improves patient outcomes, offering a new therapeutic option for these challenging cancers.
Area of Science:
- Oncology
- Medical Physics
- Clinical Research
Background:
- High-risk soft tissue sarcomas require effective preoperative treatment strategies.
- Prognostic factors like tumor size, grade, depth, and margins are crucial for patient stratification.
- Previous research focused on radiochemotherapy or chemotherapy alone with limited evidence.
Purpose of the Study:
- To review recent developments in preoperative treatment strategies for high-risk soft tissue sarcomas.
- To emphasize the role of regional hyperthermia (RHT) combined with chemotherapy.
- To evaluate the efficacy of RHT in improving patient outcomes.
Main Methods:
- Review of recent clinical research and studies on preoperative treatments for soft tissue sarcomas.
- Analysis of phase II studies investigating regional hyperthermia (RHT) combined with chemotherapy.
- Inclusion of preliminary results from a European Organization for Research and Treatment of Cancer-European Society of Hyperthermic Oncology intergroup randomized phase III trial.
Main Results:
- Prognostic factors for localized soft tissue sarcomas are defined for patient stratification.
- Phase II studies suggest a potential benefit of RHT in combination with chemotherapy.
- A phase III trial demonstrated a significant clinical outcome benefit for patients receiving RHT.
Conclusions:
- Regional hyperthermia (RHT) combined with chemotherapy is an effective preoperative treatment option.
- This combination therapy offers a new therapeutic strategy for high-risk soft tissue sarcomas.
- RHT enhances the efficacy of chemotherapy in treating high-risk soft tissue sarcomas.
Related Concept Videos
01:25Increased Body Temperature
A body temperature above 38°C (100.4 °F) is known as fever or pyrexia, and a person with fever is termed 'febrile.' Typically, the hypothalamus, a part of the brain that acts as the body's thermostat, regulates body temperature through a thermoregulatory setpoint. It receives signals from cold and warm thermal receptors throughout the body and adjusts the body's temperature accordingly. Fever occurs when this hypothalamic setpoint is altered, usually in response to an infection or illness.
01:29Decreased Body Temperature
A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by sustained extreme cold exposure, and severe...
01:19Homeostatic Imbalances in Body Temperature
Hyperthermia occurs when the body's temperature becomes unusually high, often due to heat exposure, intense physical activity, or certain illnesses. This condition can create a dangerous cycle where elevated body temperature increases the metabolic rate, generating more heat and potentially leading to organ failure and brain damage. A severe form of hyperthermia, called heat stroke, can raise body temperature to life-threatening levels. Fever, on the other hand, is a controlled form of...